Lupin Manufacturing Solutions (LMS), a wholly owned subsidiary of global pharma major Lupin, has commissioned a dedicated oncology manufacturing block at its Vizag facility in India.

The new high-containment unit marks a significant expansion of LMS’s end-to-end Contract Development and Manufacturing (CDMO) capabilities for high-potent active pharmaceutical ingredients (HPAPIs). It will enable the company to support clients across the oncology development lifecycle from preclinical research to commercial manufacturing, addressing growing global demand for oncology drug development and manufacturing.  

Spanning 4,270 square meters, the new facility is equipped with 20 reactors, ranging from 250L to 2000L, with over 20 isolators and advanced containment systems, ensuring exposure levels of ≤0.05 µg/m³. Designed with flexible scale-up capabilities (1–35 kg batch range) and comprehensive environmental controls (≤25°C, ≤45% RH), the facility ensures safe, efficient and compliant production of oncology APIs that meet global quality standards.  

Dr. Abdelaziz Toumi, CEO, Lupin Manufacturing Solutions, said, “The inauguration of our oncology block in Vizag exemplifies our commitment to advancing oncology research and manufacturing. This state-of-the-art facility enhances our capacity to produce high-quality APIs and develop impactful therapies that benefit patients globally.”

He noted that the expansion represents a major milestone in LMS’s journey toward becoming a dedicated and trusted CDMO partner for oncology innovators:

“With a focus on containment excellence, scalable solutions tailored to each phase, and scientific rigor, this investment enables our global clients to deliver life-changing oncology treatments to patients more quickly, while upholding the highest safety and compliance standards,” he added.

The new facility integrates the Process Development Laboratory with a dedicated Quality Control laboratory, supporting early-stage route scouting, analytical development, process optimisation and validation—all in one location.

According to Lupin, the facility is equipped with isolator-based operations at every process step, integrated SCADA systems, and a robust effluent detoxification system that complies with stringent global regulatory norms and the company’s own environmental and quality standards.